With a price-to-sales (or "P/S") ratio of 1.2x Avillion Berhad (KLSE:AVI) may be sending bullish signals at the moment, given that almost half of all the Hospitality companies in Malaysia have P/S ...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis Phase IIIb clinical development of Airsupra was conducted by Avillion under an ...

UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Merck KGaA as an alternative to drugs like Novartis' Cosentyx. The ...

Merck KGaA is partnering Phase II and Phase III development of its therapeutic anti-interleukin-17 (IL-17) A/F Nanobody ® (M1095; ALX-0761) for treating plaque psoriasis, with Avillion, a U.K.-based ...

Avillion Bhd said it has introduced measures to navigate through the challenging times following its considerable FY2023 net loss. Avillion Bhd’s auditor has put a question mark on the loss-making ...

An asthma rescue inhaler from partners AstraZeneca and Avillion has won FDA approval, giving patients the option of a single product that both manages symptoms and controls underlying inflammation.

All Primary and Secondary endpoints met with high statistical significance Sonelokimab is a novel, investigational tri-specific Nanobody® that neutralizes both IL-17A and IL-17F Trial completed under ...

PETALING JAYA: Avillion Bhd has fixed the issue price for the second tranche of its private placement exercise at 12 sen per placement share, allowing it to raise a maximum of RM15.2mil in cash. The ...

London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca’s Airsupra (albuterol/budesonide) in patients with ...